• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded on in 1984 and is headquartered in Dublin, Ireland.
Market Cap | 63.504 Billion | Shares Outstanding | 329.002 Million | Avg 30-day Volume | 4.992 Million |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -4.56 |
Price to Revenue | 0.0 | Debt to Equity | 1.6837 | EBITDA | 746.7 Million |
Price to Book Value | 0.0 | Operating Margin | -4.3133 | Enterprise Value | 0 |
Current Ratio | 1.451 | EPS Growth | -4.398 | Quick Ratio | 0.62 |
1 Yr BETA | 0.4731 | 52-week High/Low | 0.0 / | Profit Margin | -7.4995 |
Operating Cash Flow Growth | 17.041 | Altman Z-Score | 0.0 | Free Cash Flow to Firm | -5.215 Billion |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
No longer subject to file | 2020-05-08 | 0 | |
|
No longer subject to file | 2020-05-08 | 0 | |
|
No longer subject to file | 2020-05-08 | 0 | |
|
No longer subject to file | 2020-05-08 | 0 | |
SAUNDERS BRENT L CHAIRMAN, PRESIDENT AND CEO |
|
No longer subject to file | 2020-05-08 | 0 |
WALSH MATTHEW M EVP, CHIEF FINANCIAL OFFICER |
|
No longer subject to file | 2020-05-08 | 0 |
|
No longer subject to file | 2020-05-08 | 0 | |
|
No longer subject to file | 2020-05-08 | 0 | |
|
No longer subject to file | 2020-05-08 | 0 | |
MEURY WILLIAM EVP & CHIEF COMMERCIAL OFFICER |
|
No longer subject to file | 2020-05-08 | 0 |
|
No longer subject to file | 2020-05-08 | 0 | |
DARECCA JAMES SVP CHIEF ACCOUNTING OFFICER |
|
No longer subject to file | 2020-05-08 | 0 |
BAILEY A ROBERT D EVP CHIEF LEGAL OFF & CORP SEC |
|
No longer subject to file | 2020-05-08 | 0 |
NICHOLSON C. DAVID EVP CHIEF R&D OFFICER |
|
No longer subject to file | 2020-05-08 | 0 |
|
No longer subject to file | 2020-05-08 | 0 | |
SWANTON WAYNE R EVP, GLOBAL OPERATIONS |
|
No longer subject to file | 2020-05-08 | 0 |
|
No longer subject to file | 2020-05-08 | 0 | |
|
25,081 | 2019-04-30 | 0 | |
LING KAREN EVP & CHIEF H.R. OFFICER |
|
25,132 | 2019-04-03 | 0 |
|
29,675 | 2018-05-02 | 0 | |
|
383,729 | 2018-05-02 | 0 | |
|
6,633 | 2018-05-02 | 0 | |
HILADO MARIA TERESA EXECUTIVE VICE PRESIDENT |
|
25,911 | 2018-04-03 | 0 |
|
25,305 | 2017-12-31 | 0 | |
STEWART ROBERT A CHIEF OPERATING OFFICER |
|
No longer subject to file | 2017-12-29 | 0 |
PRINCEN MARC EVP AND PRESIDENT INT'L COMML |
|
11,790 | 2017-05-04 | 0 |
|
11,163 | 2017-05-03 | 0 | |
|
No longer subject to file | 2017-05-03 | 0 | |
SCHAISON PHILIPPE EVP, PRESIDENT ALLERGAN MED |
|
No longer subject to file | 2016-06-08 | 0 |
NAVARRE PAUL EVP, PRESIDENT INT'L BRANDS |
|
No longer subject to file | 2016-06-08 | 0 |
|
No longer subject to file | 2015-03-17 | 0 | |
|
No longer subject to file | 2015-03-17 | 0 | |
|
No longer subject to file | 2015-03-17 | 0 | |
|
No longer subject to file | 2015-03-17 | 0 | |
BUCHEN DAVID A SEE REMARKS |
|
74,050 | 2015-03-05 | 0 |
MAYR CHARLES M CHIEF COMMUNIC OFFICER |
|
15,037 | 2015-03-05 | 0 |
PAONESSA ALBERT III PRESIDENT ANDA, INC. |
|
21,856 | 2014-09-08 | 0 |
JOYCE R TODD CHIEF FINANCIAL OFFICER |
|
0 | 2014-07-01 | 0 |
FRIDRIKSDOTTIR HAFRUN SVP, GLOBAL R&D |
|
6,914 | 2014-05-09 | 0 |
WILKINSON GEORGE FRED PRES-ACTAVIS SPECIALTY BRANDS |
|
15,412 | 2013-11-27 | 0 |
OLAFSSON SIGURDUR O PRES.-ACTAVIS PHARMA |
|
71,947 | 2013-11-11 | 0 |
EBERT CHARLES D SVP, BRANDS R&D |
|
7,611 | 2013-11-06 | 0 |
EAGAN PATRICK CHIEF HR OFFICER-GLOBAL |
|
7,009 | 2013-11-04 | 0 |
|
No longer subject to file | 2013-10-01 | 0 | |
|
No longer subject to file | 2013-10-01 | 0 | |
|
No longer subject to file | 2013-10-01 | 0 | |
|
No longer subject to file | 2013-10-01 | 0 | |
MENARD FRANCOIS A SVP,GLOBAL GENERICS R&D |
|
37,016 | 2012-05-29 | 0 |
|
6,064 | 2012-05-11 | 0 | |
CARMICHAEL CLARE SR VP, HUMAN RESOURCES |
|
16,447 | 2011-03-05 | 0 |
RUSSILLO THOMAS R EVP, GLOBAL GENERICS |
|
57,868 | 2010-12-31 | 0 |
MUNRO GORDON SR. VP, QUALITY ASSURANCE |
|
18,861 | 2010-03-16 | 0 |
BOYER ANDREW S SVP,SALES&MKTG,US GENERICS |
|
38,913 | 2010-03-14 | 0 |
MIRANDA DIANE F VP,GENERIC MARKETING & OPER. |
|
19,089 | 2010-03-14 | 0 |
AMATO LYNNE VP, BRAND SALES & OPERATIONS |
|
18,443 | 2010-03-14 | 0 |
GIORDANO THOMAS R SR VP AND CIO |
|
31,052 | 2010-03-14 | 0 |
HEIMERS EDWARD F JR EVP AND PRESIDENT, BRAND DIV. |
|
21,826 | 2010-03-14 | 0 |
POWER ANNA SR VP,GLOBAL GENERICS |
|
6,800 | 2010-02-24 | 0 |
EISENHAUR PATRICIA L. VP, INVESTOR RELATIONS |
|
7,865 | 2009-08-12 | 0 |
BRUNNER PATRICK G. SVP,MANUFACTURING OPERATIONS |
|
21,033 | 2009-07-18 | 0 |
DURAND MARK SRVP & CFO |
|
33,966 | 2009-03-05 | 0 |
SKARA SUSAN K SR. VP, HUMAN RESOURCES |
|
No longer subject to file | 2008-09-01 | 0 |
HSIA DAVID C SR. VP, SCIENTIFIC AFFAIRS |
|
1,725,515 | 2008-09-01 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2020-05-04 20:55:36 -0400 | 2022-05-01 | F | 991 | $189.74 | d | 6,352 | direct | 0.5758 | 0.5758 | 2 | 0.0 | 1 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|
Holder | Issuer | Net Short Position | Position Date | Origin |
---|